220 related articles for article (PubMed ID: 18272574)
61. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism.
Franca R; Spadari S; Maga G
Med Sci Monit; 2006 May; 12(5):RA92-8. PubMed ID: 16641889
[TBL] [Abstract][Full Text] [Related]
62. Advantages and disadvantages of cytidine deamination.
Cascalho M
J Immunol; 2004 Jun; 172(11):6513-8. PubMed ID: 15153462
[TBL] [Abstract][Full Text] [Related]
63. SMUG1 but not UNG DNA glycosylase contributes to the cellular response to recovery from 5-fluorouracil induced replication stress.
Nagaria P; Svilar D; Brown AR; Wang XH; Sobol RW; Wyatt MD
Mutat Res; 2013; 743-744():26-32. PubMed ID: 23253900
[TBL] [Abstract][Full Text] [Related]
64. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature of APOBEC3G.
Henry M; Guétard D; Suspène R; Rusniok C; Wain-Hobson S; Vartanian JP
PLoS One; 2009; 4(1):e4277. PubMed ID: 19169351
[TBL] [Abstract][Full Text] [Related]
65. HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.
Argyris EG; Pomerantz RJ
Trends Microbiol; 2004 Apr; 12(4):145-8. PubMed ID: 15116720
[No Abstract] [Full Text] [Related]
66. Inhibition of alpharetrovirus replication by a range of human APOBEC3 proteins.
Wiegand HL; Cullen BR
J Virol; 2007 Dec; 81(24):13694-9. PubMed ID: 17913830
[TBL] [Abstract][Full Text] [Related]
67. Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.
Kobayashi T; Koizumi Y; Takeuchi JS; Misawa N; Kimura Y; Morita S; Aihara K; Koyanagi Y; Iwami S; Sato K
J Virol; 2014 May; 88(10):5881-7. PubMed ID: 24623435
[TBL] [Abstract][Full Text] [Related]
68. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair.
Nowarski R; Wilner OI; Cheshin O; Shahar OD; Kenig E; Baraz L; Britan-Rosich E; Nagler A; Harris RS; Goldberg M; Willner I; Kotler M
Blood; 2012 Jul; 120(2):366-75. PubMed ID: 22645179
[TBL] [Abstract][Full Text] [Related]
69. [Advances in the study of molecular mechanism of APOBEC3G anti-HIV-1].
Fan B; Cen S; Jiang JD
Yao Xue Xue Bao; 2008 Jul; 43(7):678-82. PubMed ID: 18819469
[TBL] [Abstract][Full Text] [Related]
70. Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells.
Kamata M; Nagaoka Y; Chen IS
PLoS Pathog; 2009 Mar; 5(3):e1000342. PubMed ID: 19300495
[TBL] [Abstract][Full Text] [Related]
71. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
[TBL] [Abstract][Full Text] [Related]
72. Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription.
Nair S; Zlotnick A
J Virol; 2018 May; 92(10):. PubMed ID: 29491156
[TBL] [Abstract][Full Text] [Related]
73. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
Sheehy AM; Gaddis NC; Malim MH
Nat Med; 2003 Nov; 9(11):1404-7. PubMed ID: 14528300
[TBL] [Abstract][Full Text] [Related]
74. Human APOBEC3G Prevents Emergence of Infectious Endogenous Retrovirus in Mice.
Treger RS; Tokuyama M; Dong H; Salas-Briceno K; Ross SR; Kong Y; Iwasaki A
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341050
[TBL] [Abstract][Full Text] [Related]
75. Retroviral restriction by APOBEC proteins.
Harris RS; Liddament MT
Nat Rev Immunol; 2004 Nov; 4(11):868-77. PubMed ID: 15516966
[TBL] [Abstract][Full Text] [Related]
76. RNA-binding residues in the N-terminus of APOBEC3G influence its DNA sequence specificity and retrovirus restriction efficiency.
Bélanger K; Langlois MA
Virology; 2015 Sep; 483():141-8. PubMed ID: 25974865
[TBL] [Abstract][Full Text] [Related]
77. The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution.
Rathore A; Carpenter MA; Demir Ö; Ikeda T; Li M; Shaban NM; Law EK; Anokhin D; Brown WL; Amaro RE; Harris RS
J Mol Biol; 2013 Nov; 425(22):4442-54. PubMed ID: 23938202
[TBL] [Abstract][Full Text] [Related]
78. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
79. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
Wang X; Dolan PT; Dang Y; Zheng YH
J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
[TBL] [Abstract][Full Text] [Related]
80. APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.
Chelico L; Pham P; Calabrese P; Goodman MF
Nat Struct Mol Biol; 2006 May; 13(5):392-9. PubMed ID: 16622407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
